RESEARCH OPPORTUNITIES ALERT!

Issue 22: Volume 1b
GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH)

(QUARTER: JULY – SEPTEMBER, 2015)

A Compilation by the
Research Services Unit
Office of Research, Innovation and Development (ORID)

June 2015
### Table of Contents

#### Opportunities for July 2015

- Patient Safety in the Context of Perinatal, Neonatal and Paediatric Care (R01) ................................................................. 6
- New Approaches to Synthetic Lethality for Mutant KRAS-Dependent Cancers (U01) ................................................................. 7
- Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) ......................................................... 8
- Systems Biology and Antibacterial Resistance (U01) ................................................................................................................ 9
- Molecular Mechanisms of Combination Adjuvants (U01) ........................................................................................................ 10
- Detection of Pathogen-Induced Cancer (DPIC) (R01) ............................................................................................................ 11
- Vistakon Grants ................................................................................................................................................. 12
- USAID/Nigeria Education Crisis Response ..................................................................................................................... 12
- Imaging and Biomarkers for Early Cancer Detection (R01) .................................................................................................. 13
- Detection of Pathogen-Induced Cancer (DPIC) (R01) ........................................................................................................ 14
- Connectomes Related to Human Disease (U01) ............................................................................................................. 15
- HIV Vaccine Research and Design Programme (P01) ........................................................................................................ 16
- Research Partnerships for Scaling Up Mental Health Interventions in Low and Middle-Income Countries (U19) ........................................................................................................ 17
- Epidemiology of Drug Abuse (R21) ......................................................................................................................... 18
- Mechanisms of Immune Protection from Tuberculosis among HIV-Infected Individuals (R01) ............................................................... 19
- Research in Latent Tuberculosis Infection in the Setting of HIV Co-Infection (R01) .............................................................. 20
- Limited Competition: Planning Grant for Fogarty HIV Research Training Programme for Low- and Middle-Income Country Institutions (D71) .................................................................................. 21
- Limited Competition: Fogarty HIV Research Training Programme for Low- and Middle-Income Country Institutions (D43) .................................................... 22
<table>
<thead>
<tr>
<th>Grant Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIMITED COMPETITION: FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D43)</td>
<td>23</td>
</tr>
<tr>
<td>GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01)</td>
<td>24</td>
</tr>
<tr>
<td>STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01)</td>
<td>25</td>
</tr>
<tr>
<td>APPROACHES TO ELIMINATE HIV AND OPPORTUNISTIC PATHOGENS FROM ORAL RESERVOIRS (R01)</td>
<td>26</td>
</tr>
<tr>
<td>BIOLOGICAL AND PHYSIOLOGICAL EFFECTS OF E-CIGARETTE AEROSOL MIXTURES (R01)</td>
<td>26</td>
</tr>
<tr>
<td>BIOLOGICAL AND PHYSIOLOGICAL EFFECTS OF E-CIGARETTE AEROSOL MIXTURES (R21)</td>
<td>27</td>
</tr>
<tr>
<td>APPROACHES TO ELIMINATE HIV AND OPPORTUNISTIC PATHOGENS FROM ORAL RESERVOIRS (R01)</td>
<td>28</td>
</tr>
<tr>
<td>AVANT-GARDE AWARD PROGRAMME FOR HIV/AIDS AND DRUG USE RESEARCH (DP1)</td>
<td>29</td>
</tr>
<tr>
<td>ADVANCING EXCEPTIONAL RESEARCH ON HIV/AIDS AND SUBSTANCE ABUSE (R01)</td>
<td>30</td>
</tr>
<tr>
<td><strong>OPPORTUNITIES FOR AUGUST 2015</strong></td>
<td></td>
</tr>
<tr>
<td>NEURONEXT CLINICAL TRIALS (U01)</td>
<td>31</td>
</tr>
<tr>
<td>HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R03)</td>
<td>31</td>
</tr>
<tr>
<td>NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01)</td>
<td>32</td>
</tr>
<tr>
<td>NINDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3)</td>
<td>33</td>
</tr>
<tr>
<td>BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3)</td>
<td>35</td>
</tr>
<tr>
<td>TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R03)</td>
<td>36</td>
</tr>
<tr>
<td>TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R01)</td>
<td>37</td>
</tr>
<tr>
<td>EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R21/R33)</td>
<td>39</td>
</tr>
<tr>
<td>EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R33)</td>
<td>40</td>
</tr>
<tr>
<td>INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01): AIDS-RELATED</td>
<td>41</td>
</tr>
<tr>
<td>METHODOLOGIES TO ENHANCE UNDERSTANDING OF HIV-ASSOCIATED SOCIAL DETERMINANTS (R21)</td>
<td>42</td>
</tr>
<tr>
<td>METHODOLOGIES TO ENHANCE UNDERSTANDING OF HIV-ASSOCIATED SOCIAL DETERMINANTS (R01)</td>
<td>43</td>
</tr>
<tr>
<td>CUTTING-EDGE BASIC RESEARCH AWARDS (R21)</td>
<td>44</td>
</tr>
<tr>
<td><strong>OPPORTUNITIES FOR SEPTEMBER 2015.</strong></td>
<td>45</td>
</tr>
<tr>
<td>THE ROLE OF EXOSOMES IN HIV NEUROPATHOGENESIS (R21)</td>
<td>45</td>
</tr>
<tr>
<td>THE ROLE OF EXOSOMES IN HIV NEUROPATHOGENESIS (R01)</td>
<td>46</td>
</tr>
<tr>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R01): AIDS-RELATED</td>
<td>46</td>
</tr>
<tr>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R21): AIDS-RELATED</td>
<td>47</td>
</tr>
<tr>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R03): AIDS-RELATED</td>
<td>48</td>
</tr>
<tr>
<td>PILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21): AIDS-RELATED</td>
<td>49</td>
</tr>
<tr>
<td>INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21): AIDS-RELATED</td>
<td>50</td>
</tr>
<tr>
<td>INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03): AIDS-RELATED</td>
<td>51</td>
</tr>
<tr>
<td>AIDS-SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03)</td>
<td>52</td>
</tr>
<tr>
<td>BIOENGINEERING RESEARCH PARTNERSHIPS (R01): AIDS-RELATED</td>
<td>53</td>
</tr>
<tr>
<td>GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01): AIDS-RELATED</td>
<td>54</td>
</tr>
<tr>
<td>GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R03): AIDS-RELATED</td>
<td>55</td>
</tr>
<tr>
<td>GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R21): AIDS-RELATED</td>
<td>56</td>
</tr>
<tr>
<td>PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN UROLOGIC DISORDERS (R21): AIDS-RELATED</td>
<td>57</td>
</tr>
<tr>
<td>SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21): AIDS-RELATED</td>
<td>57</td>
</tr>
<tr>
<td>SMALL GRANTS FOR NEW INVESTIGATORS TO PROMOTE DIVERSITY IN HEALTH-RELATED RESEARCH (R03): AIDS-RELATED</td>
<td>59</td>
</tr>
<tr>
<td>NIDA RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25): AIDS-RELATED</td>
<td>60</td>
</tr>
<tr>
<td>Topic</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21): AIDS-RELATED</td>
<td>61</td>
</tr>
<tr>
<td>PREVENTION RESEARCH IN MID-LIFE ADULTS (R21): AIDS-RELATED</td>
<td>62</td>
</tr>
<tr>
<td>REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33): AIDS-RELATED</td>
<td>63</td>
</tr>
<tr>
<td>NIMH RESEARCH EDUCATION MENTORING PROGRAMME FOR HIV/AIDS RESEARCHERS (R25)</td>
<td>64</td>
</tr>
<tr>
<td>PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21): AIDS-RELATED</td>
<td>64</td>
</tr>
<tr>
<td>BIOPHYSICAL AND BIOMECHANICAL ASPECTS OF EMBRYONIC DEVELOPMENT (R01)</td>
<td>65</td>
</tr>
<tr>
<td>BIOPHYSICAL AND BIOMECHANICAL ASPECTS OF EMBRYONIC DEVELOPMENT (R21)</td>
<td>66</td>
</tr>
<tr>
<td>DESIGN AND DEVELOPMENT OF NOVEL TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R21)</td>
<td>67</td>
</tr>
<tr>
<td>TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R01)</td>
<td>68</td>
</tr>
</tbody>
</table>
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and paediatric care programme. This R01 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. Proposals may address:
• the epidemiology of errors and adverse events in neonatal and paediatric care hospital units;
• medication errors;
• diagnostic errors;
• procedure-related errors;
• human factor and fatigue;
• promotion of a safety culture;
• other working conditions and systems issues;
• risk reduction and disclosure practices
Eligibility is unrestricted. This funding opportunity uses the NIH research project grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-313, which solicits applications under the NIH small grant (R03) mechanism.
Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The total project period may not exceed five years.
Ref: NIH PA-14-312 (replaces PAR-11-225).

Closing date: 05 Jul 15
Deadline information: Applications are invited from 5 September 2014 and are due by 5pm local time of applicant organisation.

Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-312.html
Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-312

Eligibility profile
Country of applicant institution: Any

Disciplines
Psychology, Public Health & Medical Law, Neonatal Disorders, Hospitalisation, Medical Informatics & Telemedicine, Paediatric Nursing, Medical Effectiveness & Patient Outcomes, Patient Care & Education, Medical Research of Selected Fields, Standards of Care, Allied Health Professions, Business & Management Studies, Pregnancy & Birth, Nursing, Maternal Health, Health Informatics, Primary Care, Health Systems, Risk Management, Quality of Care, Clinical Decision-making & Analysis, Health Psychology, Paediatrics, Public Health, Health Services & Primary Care, Safety & Accident Investigation, Law, Medical & Diagnostic Tests, Health Professions

Contact Details
NIH
Pregnancy and Perinatology Branch
NEW APPROACHES TO SYNTHETIC LETHALITY FOR MUTANT KRAS-DEPENDENT CANCERS (U01)

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its new approaches to synthetic lethality for mutant KRas-dependent cancers (U01) grants. This U01 funding opportunity supports projects which identify targets whose inhibition would induce synthetic legality in cancers dependent on the expression of mutant KRas alleles. NCI seeks to stimulate research that uses advanced or improved approaches for synthetic lethality screens that have greater specificity, reproducibility and activity in physiologically relevant model systems than those used previously in first generation screening approaches.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Investigators must interact closely with the FNLCR Ras programme, actively exchange results across the network and participate in the cross-validation of potential targets identified by other awardees.

Funding may not exceed US$750,000 in direct costs each year, and the total project period may not exceed four years.

PAR-14-314.

Closing date: 08 Jul 15
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 08 Aug 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $3,000,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-314.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences, Carcinogenesis, Cancer Studies & Oncology, Characteristics, Biological Macromolecules, Cancer Cell Biology, Biological Sciences, Protein Synthesis, Modification & Turnover, Disease Models

Contact Details
NCI
6116 Executive Boulevard
Suite 300
Bethesda, MD 20892-8322
Tel: +1 240 276 6230
Email: watsonjo@mail.nih.gov
CORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (U01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its core infrastructure and methodological research for cancer epidemiology cohorts call (U01) funding opportunity announcement. This announcement provides targeted infrastructure support for the core functions of cancer epidemiology cohorts and methodological research. This infrastructure can support existing or new CECs. This FOA qualifies the following two types of CECs:
• CECs with at least 10,000 study participants that are capable of supporting studies to examine the effects of multiple exposures and study participants’ characteristics on the risk of multiple types of cancers and cancer mortality;
• cohorts of cancer patients or survivors of at least 5,000 participants across multiple cancer sites or at least 2,000 participants diagnosed with the same or narrowly related cancer sites, to support research addressing determinants of cancer progression, recurrence, mortality, incidence and other cancer or health-related outcomes.
US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The maximum budget is US$2.5 million in direct cost per year. The maximum project period is five years.
Ref: PAR-15-104 (reissue of PAR-14-160).

Closing date: 08 Jul 15

Deadline information: Applications open on 26 February and are due by 5pm local time of applicant organisation on 1 April, 8 July and 10 November 2015, 11 March, 8 July and 10 November 2016 and 10 March 2017.
Posted date: 02 Feb 15
Award type: Research centres, Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $12,500,000

Eligibility profile
Country of applicant institution: Any
Disciplines
Cancer Studies & Oncology

Contact Details
NCI
BG 9609 Room 4E206
9609 Medical Centre Drive
Rockville MD 20850
Tel: +1 240 276 6818
Email: joanne.elena@mail.nih.gov
NEW APPROACHES TO SYNTHETIC LETHALITY FOR MUTANT KRAS-DEPENDENT CANCERS (U01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its new approaches to synthetic lethality for mutant KRas-dependent cancers (U01) grants. This U01 funding opportunity supports projects which identify targets whose inhibition would induce synthetic lethality in cancers dependent on the expression of mutant KRas alleles. NCI seeks to stimulate research that uses advanced or improved approaches for synthetic lethality screens that have greater specificity, reproducibility and activity in physiologically relevant model systems than those used previously in first generation screening approaches.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Investigators must interact closely with the FNLCR Ras programme, actively exchange results across the network and participate in the cross-validation of potential targets identified by other awardees.

Funding may not exceed US$750,000 in direct costs each year, and the total project period may not exceed four years.

Closing date: 08 Jul 15
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 08 Aug 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $3,000,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-314.html
Application form: http://www.grants.gov/web/grants/applicant/package.html#download=true&oppNum=PAR-14-314

Eligibility profile
Country of applicant institution: Any
Disciplines
Diagnostic Sciences, Carcinogenesis, Cancer Studies & Oncology, Characteristics, Biological Macromolecules, Cancer Cell Biology, Biological Sciences, Protein Synthesis, Modification & Turnover, Disease Models

Contact Details
NCI
6116 Executive Boulevard
Suite 300
Bethesda, MD 20892-8322
Tel: +1 240 276 6230
Email: watsonjo@mail.nih.gov

SYSTEMS BIOLOGY AND ANTIBACTERIAL RESISTANCE (U01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its systems biology and antibacterial resistance (U01) funding opportunity announcement. This announcement encourages research
proposals that use a multidisciplinary systems biology approach to study the molecular interaction networks of the pathogen and the host in association with antibacterial resistance or in response to treatment of antibacterial resistant infections.

The projects’ focus must be on bacterial pathogens with established antibacterial resistance. Projects focused on drug-resistant tuberculosis are not supported.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$8 million in fiscal year 2016, with funding available for up to five projects. Application budgets are limited to US$2m in total costs per year. The maximum project period is five years.

Ref: RFA-AI-14-064.

Closing date: 09 Jul 15
Deadline information: Applications open on 9 June and are due by 5pm local time of applicant organisation on 9 July 2015.
Posted date: 28 Jan 15
Award type: Directed grants to institutions, research groups etc

MOL E C U L A R ME C H A N I S M S O F C O M B I N A T I O N A D J U V A N T S (U01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its molecular mechanisms of combination adjuvants (U01) funding opportunity announcement. This announcement encourages studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are used in these studies must already have shown immune boosting activity when used individually in licensed or unlicensed vaccines. Applications should include the following elements in order to be considered responsive to this FOA:
• adjuvants that have already shown immune boosting activity when used individually in licensed or unlicensed vaccines;
• exploration of the mechanism(s) of action of combination adjuvants that have already been shown individually to be effective in stimulating an enhanced immune response to vaccination when compared with antigen alone.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$4 million in fiscal year 2016 to fund six to eight awards. Applications budgets are limited to US$350,000 in direct

Award amount max: $10,000,000
Website:
Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Bacterial Diseases, Infection Agents & Pathogens, Drug Resistance, Systems Biology

Contact Details
NIAID
BG 5601 Floor Room 7A40
5601 Fishers Lane
Rockville MD 20852
Tel: +1 301 496 1884
Email: mgiovanni@niaid.nih.gov
costs per year. The maximum project period is five years. Ref: RFA-AI-15-005.

Closing date: 09 Jul 15
Deadline information: Applications open on 9 June and are due by 5pm local time of applicant organisation on 9 July 2015.
Posted date: 11 Feb 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,750,000
Application form: 

ETECTION OF PATHOGEN-INDUCED CANCER (DPIC) (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its detection of pathogen-induced cancer (R01) grants. This R01 funding opportunity announcement aims to encourage research project that focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer. This FOA encourages research to assess molecular signatures associated with risk and early-detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer. Application budgets are not limited, but must reflect actual needs of the project. Projects may last for up to five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-190.

Closing date: 10 Jul 15
Deadline information: Deadlines on 10 July and 11 December annually until 12 December 2015. Applications due by 5pm local time of applicant organisation.
Posted date: 12 Apr 13
Award type: Directed grants to institutions, research groups etc
Application form: 

Eligibility profile
Country of applicant institution: Any
Disciplines
Immunisation Programmes & Vaccination

Contact Details
BG 5601FL Room 7B40
5601 Fishers Lane
Rockville MD 20852
Tel: +1 240 627 3575
Email: wleitner@niaid.nih.gov
VISTAKON GRANTS
American Academy of Optometry

Description:
The American Optometric Foundation invites proposals for two research grants sponsored by Vistakon. The grants are intended to encourage talented researchers to pursue full-time careers in optometry. These grants fund basic or clinical research in the area of soft contact lenses. There will be two one-year awards of US$25,000 each. The award is open to all persons in optometry and vision science.

Closing date: 20 Jul 15 (Forecast)
Deadline information: Call has not yet been announced by funder, but this is the approximate deadline we expect. This call is repeated once a year.
Posted date: 03 Mar 11
Award type: Directed grants for individual investigators
Award amount max: $25,000
Website: [http://www.aaopt.org/AOF/Programs/Faculty/Research](http://www.aaopt.org/AOF/Programs/Faculty/Research)

Eligibility profile
Country of applicant institution: Any
Disciplines
Optometry, Sensory Systems, Eye Diseases, Blindness, Vision Science, Allied Health Professions, Physiology, Prosthetic & Orthotic Devices

Contact Details
American Optometric Foundation
6110 Executive Blvd, Suite 506
Rockville, MD 20852
Tel: +1 301 984 4734
Fax: +1 301 984 4737
Email: AOF@aaoptom.org

SAID/NIGERIA EDUCATION CRISIS RESPONSE
Agency for International Development (USAID)

Description:
The Agency for International Development invites applications for its USAID/Nigeria education crisis response programme. This aims to expand enrolment in appropriate, protective and relevant educational options

Contact Details
Division of Cancer Prevention
NCI
6130 Executive Boulevard, EPN 3146
Rockville, MD 20892
Tel: +1 301 435 1594
Email: kaganj@mail.nih.gov
for the girls, boys and youth affected by violence in north-eastern Nigeria, and ensure that children and youth have continued access to an instructional routine in Adamawa and the states of Bauchi and Gombe. The following problems will be addressed:

- expected large increase in drop-out rates in affected states;
- over-crowding of classrooms and learning spaces due to influx of displaced populations;
- limited access for displaced children;
- shortage of qualified teachers and instructional materials for formal and non-formal education;
- children traumatised by violence and abductions, and families fear of sending their children to school;
- marginalisation of girls and children with disabilities;
- rising tensions between host communities and displaced populations.

Any African organisation may apply. Funding is worth between US$300,000 and US$15 million for activities lasting up to three years.

Ref: APS-620-14-000001.

**Closing date:** 22 Jul 15
**Deadline information:**
**Posted date:** 08 Sep 14
**Award type:** Directed grants to institutions, research groups etc, Development

---

**IMAGING AND BIOMARKERS FOR EARLY CANCER DETECTION (R01)**

*NIH: National Cancer Institute*

**Description:**
The National Cancer Institute invites applications for its imaging and biomarkers for early cancer detection (R01) grants. This R01 funding opportunity announcement aims to facilitate collaborative imaging and biomarker research to improve cancer screening, early cancer detection and diagnosis by integrating multi-modality imaging strategies and multiplexed biomarker methodologies. Application budgets are not limited, but must reflect actual needs of the project. Projects may last for up to five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-189
DETECTION OF PATHOGEN-INDUCED CANCER (DPIC) (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its detection of pathogen-induced cancer (R01) grants. This R01 funding opportunity announcement aims to encourage research project that focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer. This FOA encourages research to assess molecular signatures associated with risk and early-detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer. Application budgets are not limited, but must reflect actual needs of the project. Projects may last for up to five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-190.

Closing date: 10 Jul 15
Deadline information: Deadlines on 10 July and 11 December annually until 12 December 2015. Applications due by 5pm local time of applicant organisation.
Posted date: 12 Apr 13
Award type: Directed grants to institutions, research groups etc
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-190
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Human Biological Sciences, Cancer Immunology, Colorectal, Pancreatic & Stomach Cancers, Cancer Cell Biology, Carcinogenesis, Melanoma & Other Skin Cancers, Prostate & Testicular Cancers, Chemotherapy, Breast Cancer, Diagnostic Sciences, Medical & Diagnostic Tests, Molecularly Targeted Therapy, Clinical Medicine, Physiology, Non-cancerous Tumours, Lung Cancer, Cancer Studies & Oncology, Pathogenesis, Leukaemia & Other Blood Cancers, Brain Cancer, Oncology Nursing, Ovarian & Cervical Cancers, Nursing

Contact Details
----------------------------------------------
Division of Cancer Prevention
NCI
6130 Executive Boulevard, EPN 3146
Rockville, MD 20892
Tel: +1 301 435 1594
Email: kaganj@mail.nih.gov

CONNECTOMES RELATED TO HUMAN DISEASE (U01)
NIH: National Institute of Mental Health

Description:
A total of six participating institutes and centres of the National Institutes of Health invite applications for their Connectomes related to human disease (U01) grants. This U01 funding opportunity announcement aims to build on the data collected using the very well defined experimental protocols of the Human Connectome Project. Applications are sought that will apply the human Connectome data collection protocol to disease or disorder cohorts of interest to the institutes and centres participating in this FOA. These cohorts will be defined by the applicant and can include subjects with specific symptoms or conditions, with comorbid conditions, with a specific genetic profile, or other applicant defined criteria. The overall purpose of the HCP is to develop and share knowledge about the structural and functional connectivity of the human brain. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is four years. Ref: PAR-14-281.

Closing date: 14 Jul 15
Deadline information: Applications due by 5pm local time of applicant organisation on 14 November and 14 July 2015, and on 14 July 2016.
Posted date: 16 Jul 14
Award type: Directed grants to institutions, research groups etc

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Muscle Diseases, Depression & Other Mood Disorders, Cognitive Processes, Primary Care, Neuroimaging, Public Health, Health Services & Primary Care, Hearing & Otology, Diagnostic Sciences, Psychiatry, Schizophrenia & Other Psychotic Disorders, Neurology, Blindness, Vision Science, Alcoholism, Psychology, Anxiety Disorders, Sleep & Sleep Disorders, Clinical Medicine, Central Nervous System, Drug & Substance Abuse, Alzheimer’s Disease & Senile Dementia, Neuroscience, Eye Diseases, Sensory Systems

Contact Details
----------------------------------------------
NIMH
6001 Executive Boulevard
Bethesda, MD 20892-9663
Tel: +1 301 435 0778
Email: farberg@mail.nih.gov

IV VACCINE RESEARCH AND DESIGN PROGRAMME (P01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its HIV vaccine research and design programme (P01) funding opportunity announcement. This announcement supports multi-component, multidisciplinary projects that address scientific questions relevant to Aids prophylactic vaccine discovery research. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$5 million in fiscal year 2016, to fund one to three awards. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PAR-15-164 (reissue of PAR-14-206).

Closing date: 15 Jul 15
Deadline information: Applications open on 15 May and are due by 5pm local time of applicant organisation on 15 July 2015, 15 July 2016 and 14 July 2017. Applicants requesting US$500,000 or more in direct costs in any year must contact a scientific contact at least 6 weeks before submitting the application.

Award type: Directed grants to institutions, research groups etc
Award budget total: $5,000,000
Website:
Application form:
https://public.era.nih.gov/assist/public/login.do?TYPE=33554433&REALMOID=06-58b5535a-f2c3-40ec-b9ff-a06a3ed4ee18&GUID=&SMAUTHREASON=0&METHODE=GET&SAGENTNAME=-SM-938PYmoLVb4VrDeXo04LZUDVdc%2b389 9ByInEAjuSUvWNIcGfBzRpWiCiVYGCogG &TARGET=-SM-
http%3a%2f%2fpublic%2eera%2enih%2egov %2fassist

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
HIV/Aids
Description:
The National Institute of Mental Health invites applications for its research partnerships for scaling up mental health interventions in low and middle-income countries (U19) funding opportunity announcement. This announcement is for projects that address implementation questions facing designated low and middle-income countries in their efforts to scale up sustainable, evidence-based mental health interventions and eliminate the mental healthcare treatment gap for children, women and men.

The mental health treatment gap refers to the proportion of persons who need, but do not receive care. Projects should include implementation research and research capacity-building activities in LMICs in any one of the following geographical regions: East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa. The programme does not support research that can be conducted primarily in or by the US or other high income country institutions.

Applications must include the following five elements:
• proposing a research partnership that includes representatives from one or more academic institutions, government agencies and non-governmental agencies;
• proposing implementation research on scaling up sustainable, evidence-based mental health interventions within one or more LMICs;
• providing evidence that the proposed implementation research is aligned with the designated LMIC’s scale-up efforts, and that there is adequate funding and other material public or private support to ensure that the designated LMIC’s scale-up efforts will proceed or continue to proceed as planned;
• proposing a plan for building capacity in two or more LMICs, including the lead LMIC in which the implementation research is to take place, and one or more additional countries in order to conduct implementation research and to use science-based methods and information to developmental health policies and programmes
• providing evidence that the proposed research and capacity-building activities are responsive to local needs, interests and capacities.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is approximately US$3 million for fiscal year 2016 to fund approximately five awards. Application budgets are limited to US$500,000 in direct costs per year. The maximum project period is five years.

Ref: RFA-MH-16-350.

Closing date: 15 Jul 15
Deadline information: Applications open on 15 June and are due by 5pm local time of applicant organisation on 15 July 2015.
Posted date: 16 Apr 15
Award type: Directed grants to institutions, research groups etc, Development (Africa/Caribbean), Networking/collaboration
Award amount max: $500,000
Application form: https://public.era.nih.gov/assist/public/login.do?TYPE=33554433&REALMOID=06-58b5535a-f2c3-40ec-b9ff-a06a3ed4ee18&GUID=&SMAUTHREASON=0&METHOD=GET&SMAGENTNAME=-SM-938PyMoLv4vFDeXo04LZUVDVdc%2b3899ByInEAjuSUuWNIGfB2zRpiCivYGCogG&TARGET=-SM-

Eligibility profile
--------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------
Mental Health, Mental Illness, Access to Health Care, Psychiatric & Mental Health Nursing

Contact Details
--------------------------------------------------
NIMH
NSC BG Room 6219
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 3725
Email: bpringle@mail.nih.gov

EPIDEMIOLOGY OF DRUG ABUSE (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its epidemiology of drug abuse grants. These R21 grants support research projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities, and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including, but not limited to:
• individual, familial, and environmental factors associated with drug use;
• interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery, and relapse;
• co-occurring psychiatric conditions, behaviours and associated problems;
• indicators and mechanisms of risk, vulnerability, and health disparities among and between sub-populations;
• developmental and life course trajectories related to the aetiology and natural history of drug use;
• need for, access to, and utilisation of drug abuse prevention and treatment services, and the social, community, and organisational factors that influence intervention development, availability, and effectiveness.
• public health impacts of the attitudes, availability, behaviours, and products, resulting from the shifting marijuana policy environment.
This funding opportunity announcement will utilise the NIH exploratory/developmental (R21) award mechanism and runs in parallel with funding opportunity announcements of identical scientific scope, PA-15-001 that
encourages applications under the NIH research project mechanism (R01) and PA-15-002 that encourages applications under the NIH small research grant R03 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible applicants include both domestic and foreign public or private institutions as well as non-profit and for-profit organisations. PA-15-001 (replaces PA-11-231)

Closing date: 16 Jul 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 16 March, 16 July and 16 November.
Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Application form: http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
Country of applicant institution: Any

Disciplines
Youth & Adolescents, Social Behaviour & Attitudes, Diagnostic Sciences, Public Health, Health Services & Primary Care, Adolescent Paediatrics, Sociology, Health Disparities, Economic & Social Environment, Behavioural Medicine, Drug & Substance Abuse, Child Development, Medical Sociology, Psychopathology, Epidemiology, Molecular Genetics, Behavioural Studies & Social Problems, Psychology, Population Studies, Medical

Contact Detail
DESPR
National Institute on Drug Abuse, NIH/DHHS
6001 Executive Boulevard, Room 5185, MSC 9589
Bethesda MD 20892-9589
Tel: +1 301 443 6504
Email: lpezmar@nida.nih.gov

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its mechanisms of immune protection from tuberculosis among HIV-infected individuals (R01) funding opportunity announcement. This announcement supports studies characterising the genetic, epigenetic and immunological correlates of protection against tuberculosis infection in highly exposed but resistant individuals, and the interaction of these correlates with HIV infection. Multidisciplinary collaboration is encouraged, incorporating clinical studies coupled with functional experiments using samples and data from well-defined cohorts. Applicants are expected to have demonstrated access to HIV-infected individuals with clearly characterised latent tuberculosis infection resistance or pre-existing cohorts that meet the criteria for their studies. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The total budget is US$3 million in fiscal year 2015 and it will fund one to three grants.
Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Ref: RFA-AI-14072.

Closing date: 22 Jul 15
Deadline information: Applications open on 22 June and are due by 5pm local time of applicant organisation on 22 July 2015.
Posted date: 27 Mar 15
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-072.html
Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275431

Eligibility profile
Country of applicant institution: Any

Disciplines
Tuberculosis, HIV/AIDS

Contact Details
NIAID
BG 5601FL Room 9E29
5601 Fishers Lane
Rockville MD 20852
Tel: +1 240 627 3062
Email: sriniva@mail.nih.gov

Research in Latent Tuberculosis Infection in the Setting of HIV Co-Infection (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its research in latent tuberculosis infection in the setting of HIV co-infection (R01) programme. This R01 funding opportunity announcement invites grant applications which propose research to increase the understanding of the microbiologic adaptive mechanisms, host immunologic factors, and their interactions involved in the development, maintenance, and activation of LTBI with a focus on HIV co-infection.
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-061

Closing date: 24 Jul 15
Posted date: 27 Dec 12
Award type: Directed grants to institutions, research groups etc
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-061

Eligibility profile
Country of applicant institution: Any

Disciplines
Biological Markers & Sensor Mechanisms, Biological Sciences, Microbial Ecology, Immunotherapy, Immunology, Immunological & Bioassay Methods, Drug
LIMITED COMPETITION: PLANNING GRANT FOR FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D71)

NIH: Fogarty International Center

Description:
The Fogarty International Center and the National Institute of Mental Health invite applications for the limited competition: planning grant for Fogarty HIV research training programme for low- and middle-income country institutions (D71) grants. This D71 funding opportunity announcement supports research training that will strengthen the HIV research capacity of institutions in low- and middle-income countries. The planning grant application must propose a plan to develop the components necessary for an application for a research to D43 FOA. Applicants must be familiar with the objectives and special requirements of the research training programme. Institutions in low and middle-income countries are eligible to apply. Application budgets are limited to US$28,000 per year over two years. PAR-13-214 (replaces PAR-12-070).

Closing date: 24 Jul 15
Posted date: 26 Apr 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $56,000

Eligibility profile
Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines
Public Health, Health Services & Primary Care, Diagnostic Sciences, HIV/Aids, Blood Tests, Primary Care, Medical Education, Clinical Medicine

Contact Details
Fogarty International Center 31 Center Drive MSC 2220 Bethesda, MD 20892-2220 Tel: +1 301 496 1492 Email: jeanne.mcdermott@nih.gov
LIMITED COMPETITION: FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D43)
NIH: Fogarty International Center

Description:
The Fogarty International Center, the National Cancer Institute, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their limited competition: Fogarty HIV research training programme for low- and middle-income country institutions (D43) programme. This D43 funding opportunity announcement aims to support research training programmes to develop and strengthen the scientific leadership and expertise needed for HIV-related research at eligible low- and middle-income country institutions. This FOA can support training for a broad range of HIV research areas:

- all basic, epidemiologic, clinical, behavioural, social science, implementation, operations, health services and health systems research across HIV prevention, care and treatment;
- research on HIV co-infections, Aids-defining and HIV-related cancers, co-morbidities and other health conditions, both infectious and non-infectious, that contribute to HIV transmission or poor health in HIV-infected individuals;
- research and research methodology for community-based research, complex and multi-component interventions, for structural interventions, for comparative effectiveness research, for impact evaluation or for health economics;
- HIV-related research among vulnerable or under-researched LMIC populations, including women, children, substance users, men who have sex with men, transgendered populations, ageing populations, orphans and vulnerable children;
- training for clinical research team members to support clinical research and clinical trials;
- bio-statistics for research design and methodology, data analysis, data management, and data quality assurance and control;
- laboratory capacity, bio-safety and maintenance of lab quality assurance and control.

Institutions in low- and middle-income countries are eligible to apply. Application budgets are limited to US$282,000 per year over five years. PAR-13-126 (replaces PAR-12-068).

Closing date: 24 Jul 15
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,410,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-216

Eligibility profile

Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines

HIV/Aids, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, Primary Care, Computer Science & Informatics, Blood Tests, Vital Statistics & Public Records, Lesbian, Gay, Bisexual & Transgender Studies, Statistics, Theory of Computation, Behavioural Medicine, Clinical Medicine, Psychology, Data Analysis, Epidemiology, Medical Education
LIMITED COMPETITION: FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D43)

NIH: Fogarty International Center

Description:
The Fogarty International Center, the National Cancer Institute, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their limited competition: Fogarty HIV research training programme for low- and middle-income country institutions (D43) programme. This D43 funding opportunity announcement aims to support research training programmes to develop and strengthen the scientific leadership and expertise needed for HIV-related research at eligible low- and middle-income country institutions. This FOA can support training for a broad range of HIV research areas:

- all basic, epidemiologic, clinical, behavioural, social science, implementation, operations, health services and health systems research across HIV prevention, care and treatment;
- research on HIV co-infections, Aids-defining and HIV-related cancers, co-morbidities and other health conditions, both infectious and non-infectious, that contribute to HIV transmission or poor health in HIV-infected individuals;
- research and research methodology for community-based research, complex and multi-component interventions, for structural interventions, for comparative effectiveness research, for impact evaluation or for health economics;
- HIV-related research among vulnerable or under-researched LMIC populations, including women, children, substance users, men who have sex with men, transgendered populations, ageing populations, orphans and vulnerable children;
- training for clinical research team members to support clinical research and clinical trials;
- bio-statistics for research design and methodology, data analysis, data management, and data quality assurance and control;
- laboratory capacity, bio-safety and maintenance of lab quality assurance and control.

Institutions in low- and middle-income countries are eligible to apply. Application budgets are limited to US$282,000 per year over five years. PAR-13-126 (replaces PAR-12-068).

Closing date: 24 Jul 15
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,410,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-216

Eligibility profile
----------------------------------------------
Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines
---------------------------------------------------------------
HIV/Aids, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, Primary Care, Computer Science & Informatics, Blood Tests, Vital Statistics & Public Records, Lesbian, Gay, Bisexual & Transgender Studies, Statistics, Theory of Computation, Behavioural Medicine, Clinical Medicine, Psychology, Data Analysis, Epidemiology, Medical Education

Contact Details
---------------------------------------------------------------
Fogarty International Center
31 Center Drive MSC 2220
Bethesda, MD 20892-2220
Tel: +1 301 496 1492
Email: jeanne.mcdermott@nih.gov

RAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its grand opportunity in medications development for substance-use disorders (U01). This U01 funding opportunity announcement will support a diverse array of preclinical and clinical projects to accelerate the development of medication for the treatment of substance-use disorders. The goal is to fund medication studies that will have a high impact and quickly yield the necessary results to advance medications closer to approval by the US Food and Drug Administration. The aim is to enable critical medications development studies that would not be possible using traditional means.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The NIH intends to commit US$10 million to fund two to three awards in fiscal year 2013. Application budgets are limited to US$5m a year over a three-year period. PAR-13-270

Closing date: 28 Jul 15

Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 12 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $15,000,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-270

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Pharmacy & Pharmacology, Clinical Medicine, Drug & Substance Abuse, Human Biological Sciences, Primary Care, Drug Design, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, Diagnostic Sciences, Clinical Pharmacy & Pharmacology
TRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its strategic alliances for medications development to treat substance use disorders (R01). The purpose of this R01 funding opportunity announcement is to support research that advances compounds towards US Food and Drug Administration approval by leveraging NIDA funds with the strengths and resources of outside organisations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations. Application budgets for direct costs may be up to $3 million per year, but need to reflect the actual needs of the proposed project. The maximum period of support is three years. PAR-13-334 (Reissue of PAS-12-122).

Closing date: 28 Jul 15
Posted date: 20 Aug 13
Award type: Clinical trials, Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration
Award amount max: $6,000,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Methods of Drug Delivery, Diagnostic Sciences, Pharmaceutical Drugs, Drug & Substance Abuse, Drug Design, Pharmacy & Pharmacology

Contact Details
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
NIDA
NIH
9000 Rockville Pike
Bethesda, MD 20892
Tel: +1 301 443 8639
Email: imontoya@mail.nih.gov
APPROACHES TO ELIMINATE HIV AND OPPORTUNISTIC PATHOGENS FROM ORAL RESERVOIRS (R01)

**NIH: National Institutes of Health**

**Description:**
The National Institute of Dental and Craniofacial Research invites applications for its approaches to eliminate HIV and opportunistic pathogens from oral reservoirs (R01) call. The aim of this R01 funding is to support novel basic and translational research projects that focus on the biology of residual oral reservoirs for HIV and opportunistic oral pathogens. Specifically this call encourages studies on:

- purging and abolishing these pathogens after using highly active anti-retroviral therapy to induce cytopathic killing and immunoclearance;
- developing alternative strategies that directly eliminate latently infected cells in which HAART resistant HIV and opportunistic pathogens persist in oral reservoirs.

Any organisation may apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period of funding is five years.

Ref: RFA-DE-15-003

**Closing date: 28 Jul 15**

**Deadline information:** Applications are due 5pm local time of applicant organisation on 21 November 2014 and 28 July 2015.

**Posted date: 28 Aug 14**

**Award type:** Directed grants for individual investigators, Directed grants to institutions, research groups etc

**Award budget total:** $3,500,000


**Eligibility profile**

----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
HIV/Aids, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, Disease Control, Blood Tests, Venereology & Sexually Transmitted Diseases, Primary Care, Oral Medicine, Clinical Medicine, Access to Health Care, Dentistry

**Contact Details**
----------------------------------------------
National Institute of Dental and Craniofacial Research  
Tel: +1 301 594 7985  
Email: isaac@mail.nih.gov

BIOLOGICAL AND PHYSIOLOGICAL EFFECTS OF E-CIGARETTE AEROSOL MIXTURES (R01)

**NIH: National Institutes of Health**

**Description:**
The National Institute of Dental and Craniofacial Research and the Office of Disease Prevention invite applications for their biological and physiological effects of e-cigarette aerosol mixtures (R01) funding
opportunity announcement. This announcement encourages research on the biological and physiological effects of aerosol mixtures produced by electronic cigarettes on cells, tissues and organs of the oral cavity including oral and periodontal epithelia, gingiva, salivary glands, and teeth. The opportunity also supports research on elucidation of the effects of electronic cigarettes on the oral microbiome. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-DE-16-005, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism. Application budgets are limited to US$250,000 per year for a maximum project period of four years. NIH intends to fund three to four awards with a total budget of US$3 million. Ref: RFA-DE-16-004.

Closing date: 28 Jul 15
Deadline information: Applications open on 28 June and are due by 5pm local time of applicant organisation, 28 July 2015.

BIOLOGICAL AND PHYSIOLOGICAL EFFECTS OF E-CIGARETTE AEROSOL MIXTURES (R21)
NIH: National Institutes of Health

Description:
The National Institute of Dental and Craniofacial Research and the Office of Disease Prevention invite applications for their biological and physiological effects of e-cigarette aerosol mixtures (R21) funding opportunity announcement. This announcement encourages research on the biological and physiological effects of aerosol mixtures produced by electronic cigarettes on cells, tissues and organs of the oral cavity including oral and periodontal epithelia, gingiva, salivary glands, and teeth. The opportunity also supports research on elucidation of the effects of electronic cigarettes on the oral microbiome. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Award type: Directed grants to institutions, research groups etc
Award amount max: $1,000,000
Award budget total: $3,000,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Throat, Head & Neck Cancers, Smoking & Tobacco, Atmospheric Aerosols, Craniofacial Disorders, Oral Medicine, Oral & Maxillofacial Surgery, HIV/AIDS

Contact Details
----------------------------------------------
Tel: +1 301 594 4812
Email: sundarv@mail.nih.gov
This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, RFA-DE-16-004, which solicits applications under the NIH research project (R01) grant mechanism. Application budgets are limited to US$150,000 per year for a maximum project period of two years. NIH intends to fund three to four awards with a total budget of US$2 million. Ref: RFA-DE-16-005.

Closing date: 28 Jul 15
Deadline information: Applications open on 28 June and are due by 5pm local time of applicant organisation, 28 July 2015.
Posted date: 06 Mar 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $300,000
Award budget total: $2,000,000
Website:

APPROACHES TO ELIMINATE HIV AND OPPORTUNISTIC PATHOGENS FROM ORAL RESERVOIRS (R01)
NIH: National Institutes of Health

Description:
The National Institute of Dental and Craniofacial Research invites applications for its approaches to eliminate HIV and opportunistic pathogens from oral reservoirs (R01) call. The aim of this R01 funding is to support novel basic and translational research projects that focus on the biology of residual oral reservoirs for HIV and opportunistic oral pathogens. Specifically this call encourages studies on:

• purging and abolishing these pathogens after using highly active anti-retroviral therapy to induce cytopathic killing and immunoclearance;
• developing alternative strategies that directly eliminate latently infected cells in which HAART resistant HIV and opportunistic pathogens persist in oral reservoirs.

Any organisation may apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period of funding is five years.
Ref: RFA-DE-15-003

Closing date: 28 Jul 15
Deadline information: Applications are due 5pm local time of applicant organisation on 21 November 2014 and 28 July 2015.
Posted date: 28 Aug 14
Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc
Award budget total: $3,500,000

Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Oral & Maxillofacial Surgery, Atmospheric Aerosols, Craniofacial Disorders, Smoking & Tobacco, Throat, Head & Neck Cancers, HIV/Aids, Oral Medicine

Contact Details

Tel: +1 301 594 4812
Email: sundarv@mail.nih.gov
VANT-GARDE AWARD PROGRAMME FOR HIV/AIDS AND DRUG USE RESEARCH (DP1)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites for its avant-garde award programme for HIV/AIDS and drug use research. This DP1 funding opportunity supports individual scientists of exceptional creativity who propose innovative, high-impact basic research that will open new areas of HIV/AIDS research or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. Research may lead to improved prevention interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV. US or foreign for-profit and non-profit organisations may apply.
NIDA intends to commit US$2 million in FY2015, to fund two to three awards each year. Applicants may request direct costs of up to US$500,000 per year, over a maximum of five years.

Ref: RFA-DA-15-004 (reissue of RFA-DA-14-008).

Closing date: 29 Jul 15
Posted date: 14 Feb 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $2,500,000
Website:
Application form:

Eligibility profile
Country of applicant institution: Any
Disciplines
HIV/Aids, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, Disease Control, Blood Tests, Venereology & Sexually Transmitted Diseases, Primary Care, Oral Medicine, Clinical Medicine, Access to Health Care, Dentistry
ADVANCING EXCEPTIONAL RESEARCH ON HIV/AIDS AND SUBSTANCE ABUSE (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its advancing exceptional research on HIV/AIDS and substance abuse (R01) funding opportunity announcement. This announcement will support highly innovative applications on HIV/AIDS and drug abuse. Applications submitted under this FOA must have a detailed research plan and preliminary data. This FOA focuses on innovative research projects that have the potential to open new areas of HIV/AIDS research or lead to new avenues for prevention and treatment of HIV/AIDS among substance abusers. The nexus with substance abuse should be clearly described. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. NIDA intends to commit US$2 million in fiscal year 2016 to fund two to three awards. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: RFA-DA-16-001 (reissue of RFA-DA-15-005).

Closing date: 31 Jul 15
Deadline information: Applications open on 30 June and are due by 5pm local time of applicant organisation on 31 July 2015.

Posted date: 11 Feb 15
Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc, Innovation grants

Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-001.html

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids, Drug & Substance Abuse

Contact Details
NIDA
NSC BG Room 5274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 1470
Email: jnormand@nida.nih.gov
EURONEXT CLINICAL TRIALS (U01)
NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its NeuroNEXT clinical trials (U01) grants. This U01 funding opportunity announcement encourages exploratory clinical trials investigational agents that may contribute to the justification for and provide the data required to design a future trial for biomarker validation studies or for proof-of-mechanism clinical studies. Diseases studied must correlate with NINDS’s strategic plan and clinical research interests. Application budgets are not limited, but need to reflect actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Non-US entities may apply, but they will have to work with the US-based NeuroNEXT infrastructure. PAR-13-343 (replaces PAR-11-343).

Closing date: 03 Aug 15
Deadline information: Applications due by 5pm local time of applicant organisation
Deadlines on: 2 December 2013, 2 April 2014, 1 August 2014, 2 December 2014, 3 April 2015, 3 August 2015, 3 December 2015.

HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R03)
NIH: National Institute of Mental Health

Description:
Five institutes and centres of the National Institutes of Health invite applications for their high throughput screening to discover chemical probes (R03) grants. This R03 funding opportunity announcement aims to

Posted date: 02 Sep 13
Award type: Directed grants to institutions, research groups etc
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-343

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Preventive Medicine, Diagnostic Sciences, Disease Models, Laboratory Animals, Biological Markers & Sensor Mechanisms, Animal Models, Biochemical Markers, Clinical Medicine, Drug Design

Contact Details
----------------------------------------------
NINDS
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 496 9135
Email: mcneilde@ninds.nih.gov
promote and support discovery and development of new chemical probes as research tools for use to advance understanding of biological functions and disease mechanisms. The FOA encourages partnerships between assay submitters and a discovery facility to conduct joint research. Funding will stimulate research in:

- the discovery and development of novel, small molecules for their potential use in studying disease treatment;
- the discovery or validation of novel, biological targets that will inform studies of disease mechanisms.

Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-135.

Closing date: 06 Aug 15
Deadline information: Applications due by 5pm local time of applicant organisation.
Deadlines on: 6 August 2013, 4 December 2013, 4 April 2014, 6 August 2014, 4 December 2014, 3 April 2015, 6 August 2015, 4 December 2015.
Posted date: 07 Mar 13
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration

Award amount max: $100,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-135

Eligibility profile
Country of applicant institution: Any

Disciplines
Medicine & Health, Medicinal Chemistry, Diagnostic Sciences, Molecular Probes, Immunological & Bioassay Methods, Chemistry, Disease Models

Contact Details
Division of Neuroscience and Basic Behavioral Science
NIMH
6001 Executive Boulevard, Room 7182B, MSC 9641
Bethesda, MD 20892-9641
Tel: +1 301 443 6102
Email: yyao@mail.nih.gov

INDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01)
NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its cooperative research to enable and advance translational enterprises for biotechnology products and biologics discovery track: optimisation in preparation for development of biotechnology products and biologics (U01) grants. The purpose of this U01 funding opportunity announcement is the discovery of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. This FOA supports the optimisation of therapeutic leads showing convincing proof-of-concept. At the end of the funding period, projects that successfully advance through support from this
Programme will have identified an optimised candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favourable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE bio development track for further development to enable filing for an investigational new drug. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics-based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but must reflect the actual needs of the proposed project. Budgets will normally remain under US$500,000 in direct costs in any given year. The project period is typically three years and may not exceed four years.

Ref: PAR-14-286.

Closing date: 11 Aug 15
Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.
Posted date: 21 Jul 14

Award type: Directed grants to institutions, research groups etc
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-286.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacotherapy, Drug Design, Clinical Pharmacy & Pharmacology, Diagnostic Sciences, Public Health, Health Services & Primary Care, Biological Sciences, Pharmacy & Pharmacology, Methods of Drug Delivery, Neurology, Pharmacokinetics, Chemistry, Protein Synthesis, Modification & Turnover, Neuropharmacology, Clinical Medicine, Cell Physiology & Metabolism, Toxicology, Gene Therapy, Primary Care, Neurobiology

Contact Details

NIH/NINDS
Neuroscience Center, Room 2106
6001 Executive Blvd MSC
Bethesda MD 20892
Tel: +1 301 496 1779
Email: createnquiries@mail.nih.gov

INDDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3)

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its NINDS cooperative research to enable and advance translational enterprises for biotechnology products and biologics development track: preclinical and early-phase clinical development for biotechnology products and biologics (UH2/UH3) grants. The purpose of this UH2/UH3 funding
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)

opportunity announcement is the development of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favourable properties that are consistent with the desired clinical application, is required for entry to the CREATE bio development track. The FOA supports investigational new drug-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the US Food and Drug Administration, at a minimum. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics-based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Applications should rarely exceed US$1 million in direct costs per year during the UH2 phase and US$1.5 million in direct costs per year during the UH3 phase. The proposed project period for the UH2 phase may not exceed two years and the UH3 phase may not exceed four and a half years. The total duration of UH2 and UH3 phases may not exceed five years. Ref: PAR-14-288.

Closing date: 11 Aug 15
Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.

Posted date: 21 Jul 14
Award type: Directed grants to institutions, research groups etc

Website:

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Methods of Drug Delivery, Public Health, Health Services & Primary Care, Clinical Pharmacy & Pharmacology, Diagnostic Sciences, Cell Physiology & Metabolism, Pharmacokinetics, Pharmacotherapy, Toxicology, Neurobiology, Primary Care, Drug Design, Gene Therapy, Pharmacy & Pharmacology, Neurology, Biological Sciences, Clinical Medicine, Protein Synthesis, Modification & Turnover, Chemistry, Neuropharmacology

Contact Details
NIH/NINDS
Neuroscience Center, Room 2106
6001 Executive Blvd MSC
Bethesda MD 20892
Tel: +1 301 496 1779
Email: createnquiries@mail.nih.gov
BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3)

NIH: National Institute of Neurological Disorders and Stroke

Description:
A total of nine participating institutes and centres of the National Institutes of Health invite applications for their blueprint neurotherapeutics network: small molecule drug discovery and development for disorders of the nervous system (UH2/UH3) grants. The purpose of this UH2/UH3 funding opportunity announcement is to help neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organisations that specialise in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under good manufacturing practices, and phase I clinical testing. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined duration of the UH2 and UH3 award cannot exceed five years. Ref: PAR-14-293.

Closing date: 11 Aug 15
Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.
Posted date: 23 Jul 14

Award type: Directed grants to institutions, research groups etc
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Central Nervous System, Pharmacotherapy, Drug Design, Public Health, Health Services & Primary Care, Biological Sciences, Clinical Pharmacy & Pharmacology, Diagnostic Sciences, Pharmacy & Pharmacology, Neurology, Methods of Drug Delivery, Chemistry, Protein Synthesis, Modification & Turnover, Neuropharmacology, Pharmacokinetics, Cell Physiology & Metabolism, Clinical Medicine, Toxicology, Gene Therapy, Neurobiology, Primary Care

Contact Details
NIH: National Institute of Neurological Disorders and Stroke
Division of Extramural Research
6001 Executive Boulevard Suite 3309
Bethesda, MD 20892- 9531
Tel: +1 301 496 1779
Email: farkasr@ninds.nih.gov
TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for translational research in paediatric and obstetric pharmacology (R03) grants. This R03 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing foetuses. The overall goals of this funding opportunity announcement are:
• to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
• to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R03 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-309 that encourages applications under the R01 grant mechanism and PAR-13-311 that encourages applications under the R21 grant mechanism. Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-310 (replaces PAR-11-247).

Closing date: 14 Aug 15
Deadline information: Applications due by 5pm proposer’s local time.
Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-310

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Primary Care, Epigenetics, Neonatal Disorders, Biological Markers & Sensor Mechanisms, Paediatrics, Clinical Medicine, Public Health, Health Services & Primary Care, Biological Sciences, Diagnostic Sciences, Pharmacy & Pharmacology, Medical Genetics, Translational Medicine, Genomics, Pregnancy & Birth, Maternal Health, Cancer Genetics, Obstetrics & Gynaecology, Foetal Health & Prenatal Development

Contact Details
----------------------------------------------
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: +1 301 402 9340
Email: zren@mail.nih.gov
Description:
The National Institute of Child Health and Human Development invites applications for its translational research in paediatric and obstetric pharmacology (R01) grants. This R01 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing foetuses. The overall goals of this funding opportunity announcement are:
- to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R01 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-310 that encourages applications under the R03 grant mechanism and PAR-13-311 that encourages applications under the R21 grant mechanism. Application budgets are not limited but need to reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-309 (replaces PAR-11-246).

Closing date: 14 Aug 15
Deadline information: Applications due by 5pm proposer’s local time.
Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-309

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Paediatrics, Diagnostic Sciences, Public Health, Health Services & Primary Care, Primary Care, Maternal Health, Pregnancy & Birth, Translational Medicine, Genomics, Foetal Health & Prenatal Development, Cancer Genetics, Obstetrics & Gynaecology, Clinical Medicine, Biological Markers & Sensor Mechanisms, Neonatal Disorders, Epigenetics, Medical Genetics, Pharmacy & Pharmacology, Biological Sciences

Contact Details
---------------------------------------------------------------
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: +1 301 402 9340
Email: zren@mail.nih.gov
TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY
(R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for translational research in paediatric and obstetric pharmacology (R21) grants. This R21 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing foetuses. The overall goals of this funding opportunity announcement are:
• to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
• to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.
This FOA will use the R21 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-310 that encourages applications under the R03 grant mechanism and PAR-13-309 that encourages applications under the R01 grant mechanism. Direct costs are limited to US$275,000 over an R21 two-year period. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-311 (replaces PAR-11-248).

Closing date: 14 Aug 15
Deadline information: Applications due by 5pm proposer’s local time.
Posted date: 06 Aug 13
Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-311

Eligibility profile
Country of applicant institution: Any

Disciplines
Maternal Health, Pregnancy & Birth, Translational Medicine, Genomics, Foetal Health & Prenatal Development, Cancer Genetics, Obstetrics & Gynaecology, Clinical Medicine, Biological Markers & Sensor Mechanisms, Paediatrics, Neonatal Disorders, Epigenetics, Medical Genetics, Pharmacy & Pharmacology, Diagnostic Sciences, Public Health, Health Services & Primary Care, Biological Sciences, Primary Care

Contact Details
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: +1 301 402 9340
Email: zren@mail.nih.gov
EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R21/R33)
NIH: National Institute on Drug Abuse

Description:
A total of four institutes and offices of the NIH invite applications for their exploratory studies of smoking cessation interventions for people with schizophrenia (R21/R33) grants. The purpose of this R21 and R33 funding opportunity is to provide support for grant applications to generate and conduct preliminary tests of targeted smoking cessation treatments for individuals with schizophrenia. This funding opportunity announcement provides support for grant applications designed to generate novel treatments and improve existing treatments and conduct preliminary tests of novel and improved behavioural, pharmacological, and combined smoking cessation treatments for individuals with schizophrenia by examining the mechanisms of nicotine addiction in individuals with schizophrenia as putative intervention targets. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The NIH intends to fund an estimate of six to nine awards corresponding to a total of US$3.5 million for fiscal year 2015. The R21 phase may not exceed two years or US$275,000 in direct costs, with no more than US$150,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed three years or US$450,000 in direct costs, with no more than US$225,000 in direct costs in any single year of the R33 phase. The maximum period is five years.

Ref: PAR-14-230.

Closing date: 17 Aug 15
Deadline information: Applications due by 5pm local time of applicant organisation on 15 August, 16 December 2014, 15 April, 17 August, December 15, 2015, 15 April, 16 August, 15 December, 2016, 17 April until 8 September 2017.

Deadline date: 15 August, 16 December, 2014, 15 April, 16 August, 15 December, 2016, 17 April until 8 September 2017.

Website:

Application form:
http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Mental Health, Schizophrenia & Other Psychotic Disorders, Psychology, Addiction, Drug & Substance Abuse, Economic & Social Environment, Medical Sociology, Primary Care, Mental Illness, Psychiatry, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Biomedical Engineering, Sociology, Smoking & Tobacco, Health Disparities, HIV/Aids

Contact Details
NIH
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: +1 301 443 2235
Fax: +1 301 443 7397
Email: lisaonken@nih.gov
EXPLORATORY STUDIES OF SMOKING CESSTATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R33)
NIH: National Institute on Drug Abuse

Description:
A total of four institutes and offices of the NIH invite applications for their exploratory studies of smoking cessation interventions for people with schizophrenia (R33) grants. The purpose of this R33 funding opportunity is to provide support for grant applications of two major types. Type I will conduct exploratory testing of novel, targeted treatments for smoking cessation for individuals with schizophrenia. Type II will conduct exploratory testing of targeted implementation strategies of existing efficacious treatments at the service-delivery system level. Ultimately, this R33 funding mechanism intends to speed the translation of emerging basic science findings of mechanisms and processes underlying treatments or implementation strategies into novel intervention approaches that can be efficiently tested for their promise to promote smoking cessation in individuals who have schizophrenia or promote the adoption of experimentally-supported smoking cessation interventions within organisations that provide services to smokers with schizophrenia.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The NIH intends to fund an estimate of six to nine awards, corresponding to a total of US$3.5 million for fiscal year 2015. The budget may not exceed US$450,000 in direct costs over the three year project period, with no more than US$225,000 in direct costs in any single year. The maximum period is three years.

Ref: PAR-14-231.

Closing date: 17 Aug 15


Posted date: 20 May 14

Award type: Directed grants to institutions, research groups etc

Award budget total: $3,500,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse, Mental Illness, Psychiatry, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Biomedical Engineering, Mental Health, Schizophrenia & Other Psychotic Disorders, Psychology, Smoking & Tobacco, Sociology, Addiction, HIV/Aids, Health Disparities, Economic & Social Environment, Medical Sociology, Primary Care

Contact Details

NIH
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: +1 301 443 2235
Email: lisaonken@nih.gov
INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01): AIDS-RELATED
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for funding for international research in infectious diseases. This Aids-related R01 funding opportunity announcement solicits applications from organisations and institutions in resource-constrained countries that propose research related to infectious diseases. The intent is to advance the development of local scientific expertise, build local research infrastructure and to increase collaborative research partnerships at NIAID international sites.

For-profit or non-profit organisations and public or private institutions in developing countries may apply. Principal investigators may not currently hold a NIH funded grant. Collaborative projects involving investigators and institutions from international sites and the US are particularly encouraged, but a US partner is not a requirement.

Grants are worth up to US$125,000 per year over a period of up to five years.

PAR-14-080 (replaces PAR-11-145).

Closing date: 19 Aug 15
Deadline information: Application due by 5pm local time of applicant organisation.

Deadlines on: 22 August 2014, 19 August 2015, 21 August 2015.

Posted date: 31 Jan 14

Award type: Directed grants to institutions, research groups etc.

Networking/collaboration

Award amount max: $625,000

Website:


Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-145

Eligibility profile

Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines

International Health, Pathology, Respiratory Medicine, Biological Sciences, Allied Health Professions, Epidemiology, Biostatistics, Influenza, Infectious Diseases, Infection Agents & Pathogens, Gastroenterology, Parasitology, Primary Care, Virology, Immunology, Blood Tests, Human Biological Sciences, Venereology & Sexually Transmitted Diseases, Immunopathology, Malaria, Pathogenesis, Tropical & Neglected Diseases, Drug Resistance, Microbiology, Physiology, HIV/Aids, Diagnostic Sciences, Public Health, Health Services & Primary Care, Tuberculosis

Contact Details

Division of Microbiology and Infectious Diseases
NIAID
Room 3807, MSC-6603
6610 Rockledge Drive
Bethesda, MD 20892-6603
Tel: +1 301 496 1884
Email: ps31g@nih.gov
METHODOLOGIES TO ENHANCE UNDERSTANDING OF HIV-ASSOCIATED SOCIAL DETERMINANTS (R21)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their methodologies to enhance understanding of HIV-associated social determinants (R21) funding opportunity announcement. This announcement invites applications that propose to understand social determinants of health as they relate to HIV infection and disease outcomes. Specifically, this aims to support methodological innovations to advance the understanding of social determinants in order to design and support future interventions at clinic, community and social environmental levels. The use of multidisciplinary teams that draw on expertise in other health conditions or even outside of the health field is highly encouraged. Examples include behavioural economics, urban planning, political science, systems management, advanced biostatistics and demography as applied to HIV.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, RFA-MH-16-200 which solicits applications under the NIH research project (R01) grant mechanism. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The total budget is approximately US$2 million in fiscal year 2016 to fund three to four grants across this and the companion FOA. Application budgets are limited to US$275,000 in direct costs with a maximum of US$200,000 in direct costs per year. The maximum project period is two years.

Ref: RFA-MH-16-205.

Closing date: 19 Aug 15
Deadline information: Applications open on 19 July and are due by 5pm local time of applicant organisation on 19 August 2015.
Posted date: 25 Mar 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Website:
Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275365

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
HIV/Aids

Contact Details
----------------------------------------------
NIMH
BG 5601FL Room 9G19
5601 Fishers Lane
Rockville MD 20852
Tel: +1 240 627 3868
Email: grossmanc@mail.nih.gov
METHODOLOGIES TO ENHANCE UNDERSTANDING OF HIV-ASSOCIATED SOCIAL DETERMINANTS (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their methodologies to enhance understanding of HIV-associated social determinants (R01) funding opportunity announcement. This announcement invites applications that propose to understand social determinants of health as they relate to HIV infection and disease outcomes. Specifically, this aims to support methodological innovations to advance the understanding of social determinants in order to design and support future interventions at clinic, community and social environmental levels. The use of multidisciplinary teams that draw on expertise in other health conditions or even outside of the health field is highly encouraged. Examples include behavioural economics, urban planning, political science, systems management, advanced biostatistics and demography as applied to HIV.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-MH-16-205 which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The total budget is approximately US$2 million in fiscal year 2016 to fund three to four grants across this and the companion FOA.

Application budgets are not limited but should reflect the actual needs of the proposed project. The maximum project period is five years.
Ref: RFA-MH-16-200.

Closing date: 19 Aug 15
Deadline information: Applications open on 19 July and are due by 5pm local time of applicant organisation on 19 August 2015.
Posted date: 25 Mar 15
Award type: Directed grants to institutions, research groups etc
Website:
Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275381

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids

Contact Details

NIMH
BG 5601FL Room 9G19
5601 Fishers Lane
Rockville MD 20852
Tel: +1 240 627 3868
Email: grossmanc@mail.nih.gov
CUTTING-EDGE BASIC RESEARCH AWARDS (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its cutting-edge basic research awards (R21) funding opportunity announcement. This announcement aims to foster highly innovative or conceptually creative research related to drug abuse and addiction and how to prevent and treat them. Awards support research that is high-risk and potentially high-impact that is underrepresented or not included in NIDA’s current portfolio. The proposed research should:

• test a highly novel and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would have a substantial impact on current thinking;
• develop or adapt innovative techniques or methods for addiction research, or that have promising future applicability to drug abuse research.

Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are limited to US$125,000 per year in direct costs over a maximum two-year project period.

Ref: PAR-15-079 (replaces PAR-12-086).

Closing date: 20 Aug 15
Deadline information: Applications open on 20 July 2015 and are due at 5pm local time of applicant organisation on each deadline date. Deadlines on: 20 August 2015, 18 December 2015, 19 August 2016, 20 December 2016, 18 August 2017, 20 December 2017.

Posted date: 09 Jan 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: $250,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction, Drug & Substance Abuse

Contact Details

NIDA
NSC Building, Room 4253
6001 Executive Boulevard
Rockville, MD 20852
Tel: +1 301 435 1315
Email: svolman@mail.n
THE ROLE OF EXOSOMES IN HIV NEUROPATHOGENESIS (R21)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke invite applications for their role of exosomes in HIV neuropathogenesis (R21) funding opportunity announcement. This announcement invites small research grant applications focused on defining the central role of exosomes in the neuropathogenesis of HIV-1 associated neurocognitive disorders and determining the potential use of exosomes as biomarkers for HAND or as delivery vehicles for central nervous system targeted therapeutics. Multidisciplinary research teams and collaborative alliances are encouraged but not required. This FOA uses the NIH exploratory/developmental grant (R21) mechanism and runs in parallel with a FOA of similar scientific scope, RFA-MH-16-100 that solicits applications under the research project grant (R01) mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are limited to US$275,000 with a maximum of US$200,000 per year in direct costs. The maximum project period is two years.

Ref: RFA-MH-16-110.

Closing date: 02 Sep 15
Deadline information: Applications open on 2 August and are due by 5pm local time of applicant organisation, 2 September 2015.
Posted date: 20 Mar 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Website:
Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275323

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
HIV/Aids

Contact Details
----------------------------------------------
BG 5601 FL Room 9G20
5601 Fishers Lane
Rockville MD 20852
Tel: +1 240 627 3869
Email: ijeymoha@mail.nih.gov
THE ROLE OF EXOSOMES IN HIV NEUROPATHOGENESIS (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke invite applications for their role of exosomes in HIV neuropathogenesis (R21) funding opportunity announcement. This announcement supports projects focused on defining the central role of exosomes in the neuropathogenesis of HIV-1 associated neurocognitive disorders (HAND), and determining the potential use of exosomes as biomarkers for HAND or as delivery vehicles for central nervous system targeted therapeutics. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

This FOA uses the NIH research project grant (R01) mechanism and runs in parallel with a FOA of similar scientific scope, RFA-MH-16-110, which solicits applications under the exploratory/developmental grant (R21) mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Project budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: RFA-MH-16-100.

Closing date: 02 Sep 15

Drug Abuse Prevention Intervention Research (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R01) funding opportunity announcement. This Aids-related announcement aims to support research that
will employ rigourous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan. This FOA encourages investigations of cognitive, behavioural, and social processes as they relate to:

• development of novel prevention approaches;
• efficacy and effectiveness of prevention interventions or programmes;
• processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
• methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This FOA uses the research project grant (R01) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-081 which respectively use the exploratory/developmental grant (R21) and the small grant programme (R03) funding mechanism.

Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years. Ref: PA-15-082 (reissue of PA-11-311).

Closing date: 07 Sep 15

Deadline information: Applications open on 5 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 12 Jan 15

Award type: Directed grants to institutions, research groups etc


Eligibility profile

Country of applicant institution: Any

Disciplines

Smoking & Tobacco, Alcoholism, Drug & Substance Abuse, HIV/Aids

Contact Details

Prevention Research Branch
Division of Epidemiology, Services and Prevention Research
NIDA
6001 Executive Blvd, Suite 5160
Bethesda, MD 20892-9589
Tel: +1 301 443 6504
Fax: +1 301 443 2636
Email: pconway@nida.nih.gov
increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan. This FOA encourages investigations of cognitive, behavioral, and social processes as they relate to:
• development of novel prevention approaches;
• efficacy and effectiveness of prevention interventions or programmes;
• processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
• methodologies appropriate for studying complex aspects of prevention science.
Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.
This FOA uses the exploratory/developmental grant (R21) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-081 and PA-15-082 which respectively use the small grant programme (R03) and the research project grant (R01) funding mechanism.
Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Ref: PA-15-080 (reissue of PA-11-312)

Closing date: 07 Sep 15

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 12 Jan 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Smoking & Tobacco, HIV/Aids, Drug & Substance Abuse, Alcoholism

Contact Details
----------------------------------------------
NIDA
NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6504
Email: hperl@mail.nih.gov

D Rug Abuse Prevention Intervention Research (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R03) funding opportunity announcement. This Aids-related announcement aims to support research that will employ rigourous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug
use prevention within diverse populations and settings and across the lifespan. This FOA encourages investigations of cognitive, behavioural, and social processes as they relate to:

• development of novel prevention approaches;
• efficacy and effectiveness of prevention interventions or programmes;
• processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
• methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the small grant programme (R03) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-082 which respectively use the exploratory/developmental grant (R21) and the research project grant (R01) funding mechanism.

Direct costs of up to US$50,000 per year and a project duration of up to two years may be requested.

Ref: PA-15-081 (reissue of PA-11-313).

Closing date: 07 Sep 15

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 12 Jan 15

Award type: Directed grants to institutions, research groups etc

Award amount max: $100,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism, HIV/AIDS, Drug & Substance Abuse, Smoking & Tobacco

Contact Details

NIDA
NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6504
Email: hperl@mail.nih.gov

PILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its pilot and feasibility clinical trials in diabetes, and endocrine and metabolic diseases (R21) funding opportunity announcement. This Aids-related announcement supports pilot and feasibility trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention or treatment of diabetes or
selected endocrine and genetic metabolic diseases. 
US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Foreign applications must reflect special opportunities, and must be applicable to US healthcare systems to be considered for funding.
Application budgets are limited to a total of US$275,000 in direct costs, with a maximum of US$200,000 in direct costs per year. The maximum project period is two years.
Ref: PA-15-176 (reissue of PA-12-157).

Closing date: 07 Sep 15
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 07 Apr 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $275,000

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R01) research opportunity announcement. This Aids-related announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/Aids and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.
This funding opportunity uses the NIH exploratory research project grant (R21) mechanism and runs in parallel with two of identical scientific scope, PA-15-141 and PA-15-142 which respectively solicit applications.
under the NIH small grant programme (R03) mechanism and the NIH research project grant (R01) mechanism. Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are limited to US$275,000 with a maximum of US$200,000 in indirect costs per year. The maximum project period is two years.

Ref: PA-15-143 (reissue of PA-12-041).

Closing date: 07 Sep 15
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 18 Mar 15
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award amount max: $275,000

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R03) research opportunity announcement. This Aids-related announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/Aids and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH small grant programme (R03) mechanism and runs in parallel with two of identical scientific scope, PA-15-142 and PA-15-143 which respectively solicit applications under the


Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism, Drug & Substance Abuse, Smoking & Tobacco, HIV/Aids

Contact Details

National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov
NIH research project grant programme (R01) mechanism and the NIH exploratory/developmental grant (R21) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are limited US$50,000 per year over a maximum project period of two years.

Ref: PA-15-141 (reissue of PA-12-042).

Closing date: 07 Sep 15
Deadline information: Applications open on 16 May and are due by 5 pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 18 Mar 15
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $100,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism, HIV/Aids, Smoking & Tobacco, Drug & Substance Abuse

Contact Details

National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov

IDS-SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-science track award for research transition programme. This R03 funding opportunity announcement seeks to facilitate the entry of new and early-career investigators to the area of drug abuse research on HIV/Aids. To promote the entry of new investigators into research on the natural history, epidemiology, aetiology and pathogenesis, prevention and treatment of Aids in drug abusers, the FOA will support the following types of projects:

- pilot or feasibility studies;
- secondary analysis of existing data;
- small, self-contained research projects;
- development of research methodology;
- development of new research technology.

Applicants may request direct costs of up to US$100,000 per year over a project duration of up to two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

PA-12-282 (replaces PAR-10-021).

Closing date: 07 Sep 15
Deadline information: Applications due by 5 pm local time of applicant organisation.
Deadlines on: 7 September 2013, 7 September 2014, 7 September 2015.
Posted date: 11 Sep 12
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $200,000

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-282

Eligibility profile
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Epidemiology, Aetiology, Pathogenesis, Drug & Substance Abuse, Prognosis & Natural History of Disease, Primary Care, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, General Practice, HIV/AIDS

Contact Details
---------------------------------------------------------------
Division of Clinical Neuroscience and Behavioural Research
National Institute on Drug Abuse
NIH/DHHS
6001 Executive Boulevard
Room 3152, MSC 9593
Bethesda, MD 20892-9593
Tel: +1 301 443 3207
Fax: +1 301 443 6814
Email: aklinwm@mail.nih.gov

BIOENGINEERING RESEARCH PARTNERSHIPS (R01): AIDS-RELATED
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
10 participating institutes and centres of the National Institutes of Health invite applications for their Aids-related bioengineering research partnerships (R01). This Aids-related R01 funding opportunity announcement aims to accelerate the development and adoption of promising tools and technologies that can address important biomedical research problems. The objectives are to establish these tools and technologies as robust, well-characterised solutions that fulfil an unmet need and are capable of enhancing understanding of life science processes or the practice of medicine. Multidisciplinary teams should apply an integrative, quantitative bioengineering approach and engage biomedical researchers and clinicians throughout the project.

This FOA will use the NIH R01 research project grant (R01) award mechanism and runs in parallel with two FOAs of similar scientific scope, PA-12-284, which solicits applications under the R21 exploratory/developmental research grant mechanism and PAR-13-137, which also solicits applications under the R01 mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.
Ref: PAR-14-092 (replaces PAR-10-234).

Closing date: 07 Sep 15
Deadline information: Applications due by 5pm proposer’s local time. Deadlines on: 7
ENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R01) funding opportunity announcement. This Aids-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. This FOA uses the research project (R01) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-111, which solicits applications under the small grant programme (R03) and PA-15-112, which solicits applications under the exploratory/developmental (R21) grant mechanism.

Application budgets are not limited, but should reflect the needs of the project. The maximum project period is five years.


Closing date: 07 Sep 15
Deadline information: Applications open on 5 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Feb 15
Award type: Directed grants to institutions, research groups etc
Website: http://grants.nih.gov/grants/guide/pa-092.html
GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R03): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R03) funding opportunity announcement. This Aids-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. This FOA uses the small grant programme (R03) and runs in parallel with two FOAs of identical scientific scope, PA-15-110, which solicits applications under the research project (R01) grant mechanism and PA-15-112, which solicits applications under the exploratory/developmental (R21) grant mechanism. Direct costs are limited to US$50,000 per year with a maximum project period of two years. Ref: PA-15-111 (reissue of PA-11-237).

Closing date: 07 Sep 15
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 06 Feb 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
---------------------------------------------------
Country of applicant institution: Any
Disciplines
---------------------------------------------------
Medical Genetics, Alcoholism, Drug & Substance Abuse, HIV/Aids

Contact Details
---------------------------------------------------
NIDA
NSC BG Room 5150
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 402 1908
Email: nw46w@nih.gov
Genetic Epidemiology of Substance Use Disorders (R21): AIDS-Related
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R21) funding opportunity announcement. This AIDS-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-110, which solicits applications under the research project (R01) grant mechanism and PA-15-111, which solicits applications under the small grant programme (R03) mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Ref: PA-15-112 (reissue of PA-11-236).

Closing date: 07 Sep 15

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Feb 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: $275,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism, Drug & Substance Abuse, HIV/Aids, Medical Genetics

Contact Details

NIDA
NSC BG Room 5150
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 402 1908
Email: nw46w@nih.gov
Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21): AIDS-Related
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its Aids-related pilot and feasibility clinical research grants in urologic disorders (R21) funding opportunity announcement. This Aids-related announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-161, which also solicits applications under the R21 mechanism. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 in direct costs per year. The maximum project period is two years. Ref: PAR-15-162 (reissue PAR-11-352).

Closing date: 07 Sep 15

Secondary Analyses in Obesity, Diabetes, Digestive and Kidney Diseases (R21): AIDS-Related
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its secondary analyses in obesity, diabetes and digestive and kidney diseases (R21) funding opportunity announcement. This announcement supports the secondary analysis of existing data sets relevant to the following: diabetes and endocrine and metabolic diseases; genetic

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 30 Mar 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275480

Eligibility profile
Country of applicant institution: Any
Disciplines
Urology, HIV/Aids

Contact Details
NIDDK
BG 2DEM Room 627
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 77717
Email: ziya.kirkali@nih.gov
metabolic diseases; obesity, liver diseases; alimentary gastrointestinal tract diseases and nutrition; kidney, urologic and haematologic diseases. Innovative and high-risk applications with a likelihood for high impact are particularly encouraged. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are limited to a total of US$275,000 in direct costs, with up to US$200,000 available for direct costs per year. The maximum project period is two years. PA-15-169 (reissue of PA-12-125).

Closing date: 07 Sep 15

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 02 Apr 15

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: $275,000

Website:

Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275615

Eligibility profile

Country of applicant institution: Any

Disciplines

Metabolomics, HIV/AIDS, Obesity, Nutrition & Dietetics, Gastroenterology, Nephrology & Kidneys, Hormones & Endocrinology, Diabetes, Haematology, Hepatology

Contact Details

NIDDK
BG 2DEM Room 659
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 8879
Email: aynur.unalp-arida@nih.gov

PILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG ABUSE PREVENTION TRIALS (R34): AIDS-RELATED

Description:
The National Institute on Drug Abuse and the National institute on Alcohol Abuse and Alcoholism invite applications for their pilot and feasibility studies in preparation for drug and alcohol abuse prevention trials (R34) funding opportunity announcement. This Aids-related announcement supports pilot and feasibility testing of innovative new, revised or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings. It also supports pre-trial feasibility testing for prevention services and systems research. Of particular interest are prevention interventions targeting the healthcare system.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are limited to a total of US$450,000 in direct costs with up to US$225,000 in direct costs per year. The maximum project period is three years.
MALL GRANTS FOR NEW INVESTIGATORS TO PROMOTE DIVERSITY IN HEALTH-RELATED RESEARCH (R03): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Mental Health and the Office of Dietary Supplements invite applications for AIDS-related small grants for new investigators to promote diversity in health-related research (R03). This AIDS-related R03 funding opportunity announcement will provide support for new investigators from underrepresented backgrounds to conduct small research projects in the areas of research relevant to the sponsoring institutes. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources.

Direct costs are limited to US$125,000 per year for a maximum of three years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-074 (replaces PAR-09-223).

Closing date: 07 Sep 15
Posted date: 08 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $375,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-074
IDA RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related research education programme for clinical researchers and clinicians (R25) grants. This R25 funding opportunity announcement will support research education for those in clinically focused careers, in a topic area related to substance use, abuse or addiction. Participants should be training for careers as clinical researchers, clinicians or service providers, or optimally a combination of the two. This mechanism may not be used to support non-related-related clinical training. Direct costs are limited to US$350,000 in direct costs allowed in any single year. The maximum project period is five years. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-084 (replaces PAR-10-173).

Closing date: 07 Sep 15
Deadline information: Applications due by 5pm proposer’s local time. Deadlines on: 9 September 2013, 8 September 2014, 7 September 2015.
Posted date: 11 Jan 13

Award type: Personal development, Directed grants for individual investigators
Award amount max: $1,750,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-084

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Drug & Substance Abuse, HIV/Aids, Clinical Medicine, Public Health, Health Services & Primary Care, Diagnostic Sciences, Primary Care

Contact Details
---------------------------------------------------------------
Behavioural and Integrative Treatment Branch
Division of Clinical Neuroscience and Behavioural Research
NIDA
XPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and the Office of Dietary Supplements invite applications for their exploratory/developmental clinical research grants in obesity (R21) funding opportunity announcement. This Aids-related announcement supports exploratory and developmental clinical studies that accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and children. Exploratory epidemiological research with a goal of informing translational and clinical research may also be supported.
US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.
Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,00 in direct costs per year. The maximum project period is two years.
Ref: PA-15-163 (reissue of PA-12-179).

Closing date: 07 Sep 15

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 30 Mar 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000

Eligibility profile
--------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------
Obesity, HIV/Aids

Contact Details
--------------------------------------------
NIDDK
BG 2DEM Room 673
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 451 8354
Email: kuczmarskir@mail.nih.gov
PREVENTION RESEARCH IN MID-LIFE ADULTS (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute on Nursing Research and the National Institute on Ageing invite applications for their prevention research in mid-life adults (R21) funding opportunity announcement. This aids-related announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. This FOA particularly encourages interventions that can be delivered in multiple settings. Studies in disparate groups, such as African American, Native American and Hispanic populations who have a greater prevalence of illness related to multiple chronic conditions, are especially needed. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.
This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-098, which solicits applications under the NIH research project (R01) grant mechanism. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.
The combined application budget is limited to US$275,000 in direct costs over a two year period. No more than US$200,000 may be requested in any single year.
Ref: PA-15-097.

Closing date: 07 Sep 15
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 23 Jan 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Health of Minority Groups, Preventive Medicine, HIV/Aids, Geriatrics & Gerontology, Geriatric Nursing

Contact Details
NINR
BG 1Dem Room 717
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 2154
Email: mary.roary@nih.gov
REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its reductions in illicit drug use and functional outcomes (R21/R33) funding opportunity announcement. This AIDS-related announcement encourages research that determines whether reductions in illicit drug use are associated with positive changes in health-related and other functional outcomes in individuals with substance use disorders. Functional outcomes include, for example, reductions in morbidity, mortality, criminal justice involvement and overall healthcare expenditures. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by possible transition to expanded research support (R33 phase). The transition to the R33 phase will be determined by NIH programme evaluation of successful achievement of the milestones set for the R21 phase. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The R21 phase may request up to two years of support for a maximum of US$275,000 in direct costs, with no more than US$200,000 requested in any single year. The R33 phase may request up to three years of support for a maximum of US$500,000 in direct costs per year, although requests for more than US$500,000 per year may also be considered. Ref: PA-15-099.

Closing date: 07 Sep 15
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 26 Jan 15
Award type: Directed grants to institutions, research groups etc

Eligibility profile
Country of applicant institution: Any

Disciplines
Alcoholism, Drug & Substance Abuse, Health Promotion, HIV/Aids, Smoking & Tobacco

Contact Details
NSC BG Room 4131
6001 Exectutive Boulevard
Rockville MD 20852
Email: imontoya@mail.nih.gov
**NIMH RESEARCH EDUCATION MENTORING PROGRAMME FOR HIV/AIDS RESEARCHERS (R25)**

NIH: National Institute of Mental Health

**Description:**
The National Institute of Mental Health invites applications for its NIMH research education mentoring programme for HIV/AIDS researchers (R25) funding opportunity announcement. This announcement supports creative educational activities with a primary focus on mentoring activities and research experiences for HIV/AIDS researchers, that either capitalise on existing networks of collaborating investigators or develop institute-based research education programmes. Mentoring activities are expected to be primary and the cornerstone of proposed programmes though all programmes must also provide research experiences. Research education programmes are expected to enhance the professional development of the participants and foster a career trajectory towards independent research in the mental health of HIV and AIDS.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are limited to US$250,000 in direct costs per year. The maximum project period is five years.

Ref: PAR-15-145.

Closing date: 07 Sep 15

Deadline information: Applications open on 7 August 2015 and are due by 5pm local time of applicant organisation every 7 September till 8 September 2017.

Posted date: 20 Mar 15

Award type: Travel for research purposes, Directed grants to institutions, research groups etc. Equipment and materials

Award amount max: $1,250,000


**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

HIV/AIDS, Mental Health

**Contact Details**

BG 5601FL Room 9E25
5601 Fishers Lane
Rockville MD 20852
Tel : +1 240 627 3876
Email: dstoff@mail.nih.gov

---

**PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21): AIDS-RELATED**

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

**Description:**
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its Aids-related pilot and feasibility clinical research grants in kidney diseases (R21) funding opportunity announcement. This Aids-related announcement supports small scale or pilot
and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney diseases research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-162, which also solicits applications under the R21 mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 in direct costs per year. The maximum project period is two years.


Closing date: 07 Sep 15
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 30 Mar 15

BIOPHYSICAL AND BIOMECHANICAL ASPECTS OF EMBRYONIC DEVELOPMENT (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development, the National Heart, Lung and Blood Institute and the National Institute of General Medical Sciences invites applications for their biophysical and biomechanical aspects of embryonic development (R01) grants. This R01 funding opportunity announcement seeks applications that propose to advance scientific knowledge in the area of the physics and mechanics of embryonic development. Applicants must propose hypothesis-driven developmental research with the prospect of gaining new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders. Investigators are encouraged to explore approaches and concepts new to the area of developmental tissue mechanics, and use newly developed techniques superior to the ones currently used in the field. Applications require sufficient preliminary data to substantiate the validity of the
This funding opportunity announcement will use the R01 research project grant mechanism, and runs in parallel with a FOA of identical scientific scope, PAR-13-206, which encourages applications under the R21 exploratory/developmental grant mechanism. Direct costs are limited to US$500,000 per year over a maximum five-year period. Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions. PAR-13-207 (replaces PAR-10-221).

Closing date: 17 Sep 15
Deadline information: Applications due by 5pm local time of applicant organisation, 17 September annually until 18 September 2015.
Posted date: 18 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $2,500,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Growth & Growth Factors, Biological Sciences, Paediatrics, Clinical Medicine, Foetal Health & Prenatal Development, Maternal Health

Contact Details
----------------------------------------------
Developmental Biology and Structural Variation Branch
NICHD
6100 Executive Boulevard
Bethesda, MD 20892-7510
Tel: +1 301 435 6886
Email: mukhopam@mail.nih.gov

BIOPHYSICAL AND BIOMECHANICAL ASPECTS OF EMBRYONIC DEVELOPMENT (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development and the National Heart, Lung and Blood Institute invites applications for their biophysical and biomechanical aspects of embryonic development (R21) grants. This R21 funding opportunity announcement will support innovative and high-risk or high-impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this programme can explore approaches and concepts new to the area of developmental tissue mechanics; research and development of new technologies; or initial research and development of data upon which significant future research may be built. The focus of this FOA is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders. While minimal or no preliminary data are expected to be described, applications should clearly indicate the significance of the proposed work and that the proposed research or development is scientifically sound, that the qualifications of the investigators are appropriate, and that
resources available to the investigators are adequate.
This funding opportunity announcement will use the R21 exploratory/developmental grant mechanism, and runs in parallel with a FOA of identical scientific scope, PAR-13-207, which encourages applications under the R01 research project grant mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions. PAR-13-206 (replaces PAR-10-222).

Closing date: 17 Sep 15
Deadline information: Applications due by 5pm local time of applicant organisation, 17 September annually until 18 September 2015.
Posted date: 23 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

ESIGN AND DEVELOPMENT OF NOVEL TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R21)

NIH: National Institute of Biomedical Imaging and Bioengineering

**Description:**
A total of six institutes and offices of the National Institutes of Health invite applications for their design and development of novel technologies for healthy independent living (R21) grants. This R21 funding opportunity announcement supports the design and development of novel technologies to monitor health or deliver care in a real-time, accessible, effective and minimally obtrusive way. Systems may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems. Systems should also have the goal of fostering healthy and independent living.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-118, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.


Eligibility profile

Country of applicant institution: Any

Disciplines

Paediatrics, Growth & Growth Factors, Foetal Health & Prenatal Development, Maternal Health, Biological Sciences, Clinical Medicine

Contact Details

Developmental Biology and Structural Variation Branch
NICHD
6100 Executive Boulevard
Bethesda, MD 20892-7510
Tel: +1 301 435 6886
Email: mukhopam@mail.nih.gov
Ref: PAR-14-119 (replaces PAR-11-021).

Closing date: 23 Sep 15

Posted date: 27 Feb 14
Award type: Innovation grants, Networking/collaboration
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-119.html

Disciplines

Country of applicant institution: Any

Health Systems, Administration, Community Health Services, Biological Sciences, Biological Markers & Sensor Mechanisms, Assistive Technology, Health Systems, Consumer Choice, Research Management, Biotechnology, Home Health Care Services, Innovation & Technology Management, Scientific Instrumentation, Engineering Standards & Specifications, Diagnostic Sciences

Contact Details

NIBIB
Tel: +1 301 402 1337
Email: rodgersmm@mail.nih.gov

Technologies for Healthy Independent Living (R01)
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
A total of six institutes and offices of the National Institutes of Health invite applications for their technologies for healthy independent living (R01) grants. This R01 funding opportunity announcement supports research and development of technologies to monitor and deliver healthcare in a real-time, accessible, effective and minimally obtrusive way. Systems should integrate, process, analyse, communicate and present data in order to engage individuals and empower them in their own healthcare.
This funding opportunity announcement will use the NIH R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-119, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.
Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.
Ref: PAR-14-118 (replaces PAR-11-020).

Closing date: 23 Sep 15
Posted date: 27 Feb 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-118.html
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------

Contact Details
----------------------------------------------
NIBIB
Tel: +1 301 402 1337
Email: rodgersmm@mail.nih.gov